Suggested remit - To appraise the clinical and cost effectiveness of liraglutide within its marketing authorisation, for managing obesity in people aged 12 to 17.
As you are aware the Department for Health and Social Care has asked NICE to conduct an appraisal of liraglutide for managing obesity in people age 12 to 17 years. The company has informed NICE that it is unable to provide an evidence submission for this appraisal within the current timeline. Therefore, we are suspending the appraisal while we consider the next steps.
 
Status Suspended
Process STA 2018
ID number 1630

Project Team

Project lead Thomas Feist

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
12 May 2020 Suspended. As you are aware the Department for Health and Social Care has asked NICE to conduct an appraisal of liraglutide for managing obesity in people age 12 to 17 years. The company has informed NICE that it is unable to provide an evidence submission for this appraisal within the current timeline. Therefore, we are suspending the appraisal while we consider the next steps.
06 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
21 November 2019 - 19 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance